Asset Details
Do you wish to reserve the book?
Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer
Do you wish to request the book?
Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer
2024
Overview
The clinical features of sporadic mismatch repair deficiency (MMRd) and Lynch syndrome (LS) in Japanese patients with endometrial cancer (EC) were examined by evaluating the prevalence and prognostic factors of LS and sporadic MMRd in patients with EC. Targeted sequencing of five LS susceptibility genes ( MLH1 , MSH2 , MSH6 , PMS2 , and EPCAM ) was carried out in 443 patients with EC who were pathologically diagnosed with EC at the National Cancer Center Hospital between 2011 and 2018. Pathogenic variants in these genes were detected in 16 patients (3.7%). Immunohistochemistry for MMR proteins was undertaken in 337 of the 433 (77.9%) EC patients, and 91 patients (27.0%) showed absent expression of at least one MMR protein. The 13 cases of LS with MMR protein loss (93.8%) showed a favorable prognosis with a 5‐year overall survival (OS) rate of 100%, although there was no statistically significant difference between this group and the sporadic MMRd group ( p = 0.27). In the MMRd without LS group, the 5‐year OS rate was significantly worse in seven patients with an aberrant p53 expression pattern than in those with p53 WT (53.6% vs. 93.9%, log‐rank test; p = 0.0016). These results suggest that p53 abnormalities and pathogenic germline variants in MMR genes could be potential biomarkers for the molecular classification of EC with MMRd.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Aged
/ Colorectal Neoplasms, Hereditary Nonpolyposis - genetics
/ Colorectal Neoplasms, Hereditary Nonpolyposis - pathology
/ Consent
/ DNA Mismatch Repair - genetics
/ DNA-Binding Proteins - genetics
/ Endometrial Neoplasms - genetics
/ Endometrial Neoplasms - pathology
/ Epithelial Cell Adhesion Molecule - genetics
/ Epithelial Cell Adhesion Molecule - metabolism
/ Female
/ Genomes
/ Genomics
/ Humans
/ Mismatch Repair Endonuclease PMS2 - genetics
/ Mutation
/ MutL Protein Homolog 1 - genetics
/ MutS Homolog 2 Protein - genetics
/ Neoplastic Syndromes, Hereditary - genetics
/ Original
/ Patients
/ Software
/ Tumor Suppressor Protein p53 - genetics
/ Tumors
